REGISTER
MedJ at JSCO 2025 with Dr. Ken Kato
The main question is how MedJ at JSCO 2025 with Dr. Ken Kato should now be interpreted. The article traces the core results involving JSCO, III, medj and explains their implications for routine care and future research.

Ken Kato, National Cancer Center Hospital, Japan

How liquid biopsy is revolutionizing efficacy evaluation and treatment strategies in esophageal cancer, with insights into his lead international Phase III trial tracking minimal residual disease via ctDNA and other novel technologies.

0
0
Loading